Redoxis Fit for Health Europa
| Diarienummer | |
| Koordinator | Redoxis AB |
| Bidrag från Vinnova | 10 000 kronor |
| Projektets löptid | juni 2013 - juli 2013 |
| Status | Avslutat |
Viktiga resultat som projektet gav
Summary of presentations on Life science entrepreneurship; The value of biotech exits is increasing and the ROI is reasonable (median 104 milj ?). However at the same time the time for exit is increasing. The pressure to get the right project is increasing. Evaluators for the right project are depending on different factors like Team, Opportunity and Passion of the Project. The entrepreneurs need more time and resources to develop their project into assets that can be sold to further project developers for late stage clinical development, production or marketing.
Långsiktiga effekter som förväntas
Roadmap for creation of succesful R&D SMEs from investors view -Early investors are not properly rewarded for their risk -CEOs spend too much effort in raising funds -Investors form larger syndicates (that can be dysfunctional) -Question of single asset projects or building company structures - -Important for investments to be able to: -Know and explain the vision -Know what you are talking about and talk about what you do not know -Be prepared to discuss optimal A and B scenarios -Understand the funds required -Have a clear 6/12/18 months plan
Upplägg och genomförande
Medverkan i kust In the long Run 11-12 juni 2013 i Brussel. Workshop med presentationer och grupparbeten för att stärka forskning och tillväxt i små forskningsföretag Konferens Opportunities for the benefit of SMEs för att beskriva EUs forskningsfinansiering och kommande utlysningar inom H2020